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Abstract 
 
Resveratrol (3,5,4’-trihydroxystilbene, RES) is a natural product reported to display relevant 
and varied biological activity. However, its low bioavailability and rapid metabolism to its 
glucuronate and sulfate conjugates has opened a debate on the mechanisms underlying its 
bioactivity. At the same time, resveratrol derivatives and prodrugs are being developed to 
circumvent these difficulties. We have synthesized a series of resveratrol prodrugs and 
resveratrol metabolites and evaluated their cytotoxicity, VEGF expression and telomerase 
inhibition. One healthy (human embryonic kidney, HEK-293) and two tumoral cell lines 
(human colon HT-29 and breast adenocarcinoma MCF-7) were used for the assays. Cytotoxic 
measurements revealed that resveratrol glucosylated prodrugs 2-4 and piceid octanoate 7 
were more cytotoxic than resveratrol itself and more interestingly piceid 2, resveratrol-3,5-
diglucoside 3, and resveratrol-3,4’disulfate 10 combine relatively high cytotoxicity and high 
therapeutic safety margins. VEGF production in HT-29 cells was decreased by piceid 2 and 
resveratrol-3,4’disulfate 10 whereas resveratrol-3,5-diglucoside 3 and piceid octanoate 7 
diminished it to a higher extent than resveratrol. Finally, 3 and 10 were also able to inhibit the 
expression of the hTERT gen that could be correlated to a lower transcription of the c-Myc 
gene for 3 but not for RES disulfate metabolite 10. In conclusion, resveratrol prodrugs such 
as resveratrol-3,5-diglucoside 3 could be promising candidates as anticancer drugs. In 
addition, RES sulphate metabolites have shown their own biological activity indicating they 
are not simply RES reservoirs.   
 
 
INTRODUCTION 
Resveratrol (trans-3,5,4′-trihydroxystilbene, 1, see Figure 1) is a phytoalexin 
generated in response to environmental stress or pathogenic attack in grapes, blueberries, 
peanuts, cocoa and plants such as the Japanese knotweed Polygonum cuspidatum. Resveratrol 
has raised a great attention due to its relevant and varied biological activity such as its 
cardiovascular protective properties (1), antiinflammatory activity (2) or its capacity to 
extend lifespan in a variety of species (3). The cancer chemopreventive and 
chemotherapeutic potential of resveratrol has been demonstrated in different models of 
carcinogenesis in vitro and in vivo. It inhibits the proliferation of a variety of cancer cell lines 
(4) and in animal studies, resveratrol is able to interfere with the formation of azoxymethane-
(AOM) induced aberrant crypt foci in rat colon (5), reduce mammary tumour formation in N-
methyl-N-nitrosourea-(NMU) treated rats (6) or suppress prostate cancer in SV-40 tag rats 
(7). In fact, extensive in vitro studies have revealed multiple intracellular targets of 
resveratrol, which affect cell growth, inflammation, apoptosis and metastasis (8). 
Tumor angiogenesis also plays a critical role in the development of cancer. 
Resveratrol 1 and piceid (resveratrol-3-β-glucoside, 2) have shown to inhibit the formation of 
capillary-like tube formation from human umbilical vein endothelial cells (HUVEC) (9, 10). 
At the same time, vascular endothelial growth factor (VEGF) is crucial for angiogenesis and 
tumor growth, as it is involved in blood vessel development. In breast cancer cells, a 
significant decrease in extracellular levels of VEGF has been associated with apoptosis 
following resveratrol treatment (11). 
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Figure 1 
 
A relevant aspect observed in 90% of malignant tumors is the maintenance of the 
telomeres length within the cellular DNA through the expression of the telomerase reverse 
transcriptase (hTERT). This process allows cancer cells to elude the progressive shortening 
of the telomeres and finally avoid apoptosis. Resveratrol showed an inhibitory effect on 
MCF-7 tumor cell line mainly due to induce S-phase arrest and apoptosis in association with 
reduced expression of hTERT (12).  
However, as is the case with many polyphenols with putative anticancer properties, 
the bioavailability of resveratrol is very low (13). Resveratrol is well absorbed but avidly 
glucuronidated and sulphated both in the liver and in intestinal epithelial cells (14-17). In 
order to counteract this effect, high doses of resveratrol have been used in cellular, animal 
and clinical studies. This could be the cause of toxicity observed in certain cases such as in a 
multiple myeloma study in humans where 5 grams a day of a formulation of resveratrol were 
administered.  
The low amounts of resveratrol observed systemically have brought the debate on the 
possible contribution of the resveratrol metabolites to the in vivo biological activities 
attributed to resveratrol (13, 18). It has been proposed that resveratrol metabolites could 
contribute as a resveratrol reservoir through their deconjugation or that resveratrol 
metabolites could enter the cell using ABC transporters and interact directly with different 
intracellular targets (19). 
Moreover, resveratrol prodrugs are being investigated as an alternative trying to 
increase resveratrol bioavailability (20-24). We had previously prepared a family of 
resveratrol prodrugs and pro-prodrugs attaching glucosyl- or acyl- groups to resveratrol 1 or 
piceid 2 and examined their anti-inflammatory effect on an inflammatory bowel disease 
(IBD) mice model (25). We observed that oral administration of trans-resveratrol-3-O-(6’-O-
butanoyl)-β-D-glucopyranoside (6) and trans-resveratrol-3-O-(6’-O-octanoyl)-β-D-
glucopyranoside (7) produced an increase delivery of resveratrol to the colon, prevented the 
rapid metabolism of resveratrol and reduced inflammation in a murine dextran sodium 
sulphate (DSS) model. 
In the present study, we have measured cytotoxicity studies, VEGF expression and 
telomerase inhibition of five resveratrol prodrugs 3-7 modified with glucosyl- or acyl- 
groups. The idea was to find out their potential as cancer chemopreventive or 
chemotherapeutic agents either if they act as such or as a resveratrol reservoir. In addition, we 
have synthesized three resveratrol sulphate metabolites 8-10 using an improved synthetic 
route. We have also tested their biological activity and compared it with resveratrol itself 
trying to shed some light on the controversy of resveratrol metabolites biological activity. 
 
CHEMISTRY 
Diglucosylated resveratrol derivatives, trans-resveratrol-3,5-di-O-β-D-
glucopyranoside (3) and trans-resveratrol-3,5-di-O-β-D-glucopyranoside (4) were 
synthesized from resveratrol (RES, 1) as described previously (25). Briefly, mono-TBDMS 
protected resveratrol compounds obtained by random silylation of RES were glycosylated 
using 2,3,4,6-tetra-O-benzoyl-D-glucopyranosyl trichloroacetimidate as the glycosyl donor. 
Final one step deprotection under aqueous strong basic conditions yielded the desired 
products 3 and 4. Piceid acyl derivatives, trans-resveratrol-3-O-(6’-O-butanoyl)-β-D-
glucopyranoside (6) and trans-resveratrol-3-O-(6’-O-octanoyl)-β-D-glucopyranoside (7), 
were synthesized by enzymatic acylation using Thermomyces lanuginosus lipase immobilized 
on granulated silica (Lipozyme TL IM) as reported earlier (25).  
Resveratrol sulphate metabolites 8-10 were synthesized following the strategy 
reported by Hoshino et al.(26). First, TBDMS-protected resveratrol derivatives 11-15 were 
obtained from RES and each compound separated by flash column chromatography. 
However, posterior sulphation of each RES derivative using SO3.NMe3 as sulphating reagent 
under acetonitrile reflux followed by silyl deprotection resulted in very low yields (10-26%). 
Difficulties may come from no completion of the sulphation reaction and the difficult 
purification of these highly polar products.  
 
 
We have used instead microwave-assisted synthesis as reported by the group of Desai 
(27, 28) for highly sulphated organic scaffolds. TBDMS-protected resveratrol derivatives 11-
13 were treated with SO3.NMe3 and NEt3 in acetonitrile and microwaves applied at 100 ºC for 
20-40 minutes (Scheme 1). The crude was purified using LH-20 chromatography and 
desilylation was carried out using KF in MeOH during 18 h. Final crude purification was 
carried out using reversed-phase chromatography to obtain 8-10 in good yields (73-89%). 
 
Scheme 1 
 
BIOLOGICAL RESULTS AND DISCUSSION 
In vitro cytotoxicity. The cytotoxicity of resveratrol derivatives 2-7 and resveratrol 
sulphate metabolites 8-10 was evaluated in vitro against two cancer cell lines, the human 
colon adenocarcinoma HT-29 and the breast adenocarcinoma MCF-7 cell lines. In addition, 
one normal cell line, the human embryonic kidney cell line (HEK-293)  was employed in the 
assays for comparison (29). The standard MTT assay was used as described in the 
Experimental Section. Resveratrol 1 was used as the positive control. Cytotoxicity values, 
expressed as the compound concentration (µM) that causes 50% inhibition of cell growth 
(IC50), are shown in Table 1. The observed values are in most cases in the low to medium 
micromolar range. Among the resveratrol derivatives, glucosylated compounds (piceid 2, 3 
and 4) and piceid octanoate 7 showed the highest cytotoxicities for the HT-29 cell line, with 
IC50 values lower than those of resveratrol. A similar trend is observed for the MCF-7 cell 
line where the lowest IC50 values were observed for piceid 2 and piceid octanoate 7.  
Cytotoxic values have been reported for piceid 2 in several cancer cell lines with a 
wide range of IC50 values, being for example on MCF-7 cells from 1.5 to 300 µM (30-32). 
When piceid is compared with resveratrol, IC50 values were in the same range or higher (31, 
33). In our case, piceid IC50 values measured were in between those reported previously and 
in both cell lines (HT-29 and MCF-7) were lower than those obtained for resveratrol. The 
differences found in cytoxicity values for piceid may come from the different methodologies 
used to measure cell viability or from the different purity of piceid used in these studies. 
It is important to remark that glucosyl resveratrol derivatives 2-4 tested are more toxic 
for tumoral cells than for normal ones, an obviously desirable feature. This can be better 
appreciated with the α and β coefficients, obtained by dividing the IC50 values of the normal 
cell line (HEK-293) by those values of one or the other tumoral cell line (see footnote in 
Table 1). The higher value of the α or the β coefficient, the higher is the therapeutic safety 
margin of the compound in the corresponding cell line. Thus, resveratrol is relatively 
cytotoxic for the normal cell line compared with cytotoxicity exhibited in both cancer cell 
lines. In contrast, piceid 2 and 3,5-diglucosyl-resveratrol 3 show a good selectivity in the case 
of the HT-29 line (α> 5.6 and 4.2 and respectively). Zhang et al. (30) have also described that 
piceid 2 is more potent eliminating cancer cells than non-cancer cells for a variety of cell 
lines. 
Storniolo et al. has reported recently that piceid 2 inhibited Caco-2 cell growth (1-50 
µM).  Since the authors did not observed β-glucosidase activity they proposed that piceid 
presents antiproliferative effects on intestinal epithelial cells by itself and not as a resveratrol 
reservoir. This could also be the case in our assays for piceid 2 and the glycosylated RES 
derivatives 3 and 4.  However, we observed previously (25) that glucosyl- or acyl- 
modifications in resveratrol prodrugs 2, 3, 4, 6 and 7 retarded their metabolism in Caco- 2 
cells but were indeed metabolized to RES and its conjugates (glucuronates, sulfates, etc.) 
after 6-24h incubation times. Therefore, compounds 2-4, 6 and 7 seem to acting just as 
prodrugs delivering RES to the cells. 
 
Table 1. Cytotoxicity of resveratrol and compounds 2-10 [a] 
 
 HT-29 MCF-7 HEK-293 α[b] β[c] 
RES (1) 70 ± 3 127 ± 22 12 ± 3.5 0.2 0.1 
2 18 ± 8 38 ± 18 >100 >5.6 >2.6 
3 24 ±0.5 72 ± 18 >100 >4.2 >1.4 
4 45 ± 9 89 ± 16 >100 >2.2 >1.1 
5 99 ±24 115 ± 12 >100 >1.0 >0.9 
6 137 ± 20 110 ± 7 >100 >0.7 >0.9 
7 39 ± 2 52 ± 2 15 ± 4 0.4 0.3 
8 115 ± 17 17 ± 1 >100 >0.9 >5.9 
9 >100 144 ± 32 >100 >1.0 >0.7 
10 56 ± 4 26 ± 4 >100 >1.8 >3.8 
[a]IC50 values are expressed as the compound concentration (µM) that 
causes 50% inhibition of cell growth. The values are the average (± s.d.) of three 
different measurements performed as described in the Experimental section. [b]α 
= IC50 (HEK-293)/IC50 (HT-29). [c]β = IC50 (HEK-293)/IC50 (MCF-7). Values of 
α and β have been rounded off to a decimal figure. 
 
 
When cytotoxicity was measured for the resveratrol sulphated metabolites 8-10, we 
found low IC50 values for resveratrol-3-sulphate 8 and resveratrol-3,4’-disulphate 10 on 
MCF-7 cells (17 and 26 µM, respectively). In fact, these two metabolites were more toxic 
than resveratrol itself (127 µM). In the case of HT-29 cells, only resveratrol-3,4’-disulphate 
10 was slightly more toxic than resveratrol. It is relevant to point out that sulphate resveratrol 
metabolites 8-10 had low toxicity on the normal cell line HEK-293, and it is especially 
interesting the high safety margin for 8 and 10 in the MCF-7 line (β > 5.9 and 3.8, 
respectively).  
Several reports have found low or no cytoxicity (>100 µM) of resveratrol sulphated 
metabolites in a variety of cancer cells (MDA-MB-231, ZR-55-1, KB and neuroblastoma 
cells) (26, 34, 35). In contrast, more recent studies have described higher cytoxicity for 
resveratrol-3-sulphate 8 (11-35 µM) in different cancer cell lines (Caco-2, CCL-228, HCT-
116, SW620 and SW480) (36-38). In the same three studies, resveratrol 3-O-D-glucuronide 
and resveratrol 4’-O-D-glucuronide, another common resveratrol metabolites, also resulted 
cytotoxic (10-35 µM), except on SW620 and SW480 cell lines. In the specific case of MCF-7 
cells, Hoshino et al. (26) reported IC50 values >50 µM for resveratrol-3-sulphate 8. We 
obtained slightly higher toxicity for compound 8, showing similar values than the 
corresponding resveratrol-3,4’-disulphate 10. Polycarpou et al. (38) suggested that the 
differences reported on cytoxicity for the resveratrol metabolites could be due to the use of 
different assays to measure cell viability.  
Resveratrol sulfate metabolites have been suggested to provide an intracellular pool 
for resveratrol generation (39). Our results show that sulfate resveratrol metabolites are 
equally or more active as antiproliferative agents that RES itself pointing out they probably 
contribute to the in vivo biological activity observed for resveratrol. 
 
Effect of resveratrol derivatives and sulfate metabolites on VEGF production. One of 
the key factors in the angiogenesis process is the release of VEGF from cancer cells. We 
decided to examine whether our resveratrol derivatives and metabolites were able to inhibit 
or at least decrease the activation of VEGF genes in HT-29 tumoral cells. We selected for this 
study glucosylated resveratrol compounds 2 and 3, piceid octanoate 7, and resveratrol 
sulphate metabolites 8, 9 and 10. Again, resveratrol 1 was used as the positive control. We 
determined VEGF protein production by ELISA in culture supernatants. Figure 1 shows the 
results obtained in ELISA measurements after treatment of HT-29 cells with resveratrol 
derivatives in DMSO. Piceid 2, 3,5-diglucosyl-resveratrol 3, piceid octanoate 7, and 
resveratrol 3,4’-disulphate 10 decreased VEGF secretion in HT-29 cells in comparison with 
untreated cells. In fact, compounds 3 and 7 are more effective than resveratrol 1 itself.  
Piceid 2 had been shown previously to inhibit angiogenesis on human umbilical vein 
endothelial cells at concentrations of 100 to 1000 µM what is in accordance to our 
experiments. Two permethylated stilbene derivatives (40-42) and a family of resveratrol 
dimers (43) have also been reported to inhibit VEGF production. In the case of the sulfate 
resveratrol derivatives, it is surprising that resveratrol 3,4’-disulphate 10 reduces VEGF 
secretion whereas the monosulfates 8 and 9 do not. In this scenario, it is difficult to imagine 
that resveratrol 3,4’-disulphate 10 could be a resveratrol reservoir since neither resveratrol-3-
sulfate 8 or resveratrol-4’-sulfate 9 display antiangiogenic activity. 
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Figure 1. Percentage of production of VEGF from HT-29 cells treated with DMSO, 
resveratrol 1, piceid 2, 3, 7, 8, 9 and 10 (conc. 20 µg/mL for 1 and 10 µg/mL for the rest of 
compounds) related to not treated cells. At least three measurements were performed in each 
case. Bars shown represent mean values of VEGF expression percentage related to control. 
Error bars indicate standard errors of the mean. Statistical significance was evaluated using 
one-sample t-tests (P < 0.001). 
 
 Effect of resveratrol derivatives on telomerase production. Human telomerase 
contains an RNA component (hTER) that serves as a template for the addition of the repeat 
nucleotide sequences and a protein subunit (hTERT) which catalyzes the nucleotide 
polymerization process. Human telomerase is regulated during development and 
differentiation, mainly through transcriptional control of the hTERT gene, the expression of 
which is restricted to cells that exhibit telomerase activity. This indicates that hTERT is the 
rate limiting factor of the enzyme complex (44). Transcriptional factors c-Myc and Sp1 are, 
among others, implicated in the expression of the hTERT gene. These factors upregulate 
mRNA encoding the hTERT protein subunit of telomerase (45-47). Thus, and as a 
preliminary study of the potential anti-telomerase activity of resveratrol derivatives, we have 
investigated their ability to inhibit the expression of the hTERT and c-Myc genes. For that 
purpose, we selected the same group of resveratrol derivatives (2, 3 and 7) and metabolites 
(8, 9 and 10) as previously investigated for their VEGF inhibition activity. Resveratrol 1 was 
used again as control. 
The results are depicted in figures 2 and 3 and show that treatment of HT-29 cells 
with resveratrol and the aforementioned derivatives leads in fact to various degrees of 
reduction in the transcription of hTERT and c-Myc mRNA as compared with control cells. 
The most active compounds as regards to inhibition of hTERT expression are 3,5-
diglucosylated resveratrol 3 and resveratrol-3,4’-disulphate 10 which showed higher 
inhibition of hTERT gene expression than resveratrol itself. Particularly appealing is 
resveratrol metabolite 10 which was able to reduce the expression of this gene to 39% of the 
control value. For the sake of comparison, resveratrol 1 caused a reduction to 61% of the 
control value in the case of the hTERT gene. 
Regarding c-Myc inhibition our study revealed that resveratrol 1 and 3,5-diglucosyl-
resveratrol 3 are the most active compounds (48% and 66% respectively, see figure 3). 
Compounds 2, 8, 9 and 10 proved inactive in the inhibition of c-Myc gene expression. 
Resveratrol and compound 3 show some correlation between inhibition of c-Myc and hTERT 
gene expression (61% and 52%, see figure 2), indicating that resveratrol and compound 3 
could downregulate the expression of the hTERT gene by lowering the transcription of the c-
Myc gene. In contrast, this is not the case for resveratrol metabolite 10 which showed the 
highest inhibition of hTERT on this series but does not downregulate c-Myc gene expression. 
A different mechanism seems to be used by metabolite 10 pointing out again the fact that 
resveratrol-3,4’-disulfate is not just a resveratrol reservoir but instead that this resveratrol 
metabolite displays its on biological responses. 
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Figure 2. Gene expression of hTERT was normalized to that of the housekeeping gene β-
actin. At least three measurements were performed in each case. Bars shown represent mean 
values of hTERT gene expression and error bars indicate standard errors of the mean. The 
statistical significance was evaluated using one-sample t-tests (P <0.001). 
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Figure 3. Gene expression of c-Myc was normalized to that of the housekeeping gene β-actin. 
At least three measurements were performed in each case. Bars shown represent mean values 
of c-Myc gene expression and error bars indicate standard errors of the mean. The statistical 
significance was evaluated using one-sample t-tests (P <0.001). 
 
 In conclusion, resveratrol derivatives 2, 3, 4 and 7 displayed higher antiproliferative 
and antiangiogenic activity than resveratrol itself and, at the same time, these compounds 
showed less toxicity in HEK-293 cells. Most probably these derivatives are acting as RES 
prodrugs, delivering more slowly resveratrol to the cancer cells and therefore, also delaying 
RES metabolism. In the case of resveratrol sulfate metabolites 8-10, we observed equal or 
higher cytotoxicity than resveratrol in HT-29 and MCF-7 cells together with lower toxicity in 
healthy human cells. The fact that that resveratrol disulfate 10 decreases VEGF secretion but 
no activity is observed for resveratrol monosulfates 8 and 9 seems to indicate an intrinsic 
activity of 10 more than just a resveratrol reservoir. Finally, resveratrol metabolite 10 seems 
to decrease hTERT expression via a different mechanism than resveratrol itself since 10 does 
not affect c-Myc formation. These results indicate that resveratrol metabolites contribute to 
the in vivo biological activity observed for resveratrol and not only act as a resveratrol 
reservoir. 
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Experimental Section 
Chemistry: general procedures 
All chemicals obtained from commercial sources were used without further purification, 
unless otherwise noted. All reactions were monitored by TLC on precoated Silica-Gel 60 
plates F254, and detected by heating with Mostain (500 ml of 10% H2SO4, 25g of 
(NH4)6Mo7O24•4H2O, 1g Ce(SO4)2•4H2O). Products were purified by flash chromatography 
with Merck Silica gel 60 (200-400 mesh). Mass spectra analyses were run in the electrospray 
mode (ESIMS). NMR spectra were recorded on 300 or 400 MHz spectrometers, at room 
temperature for solutions in CDCl3 or D2O. Chemical shifts are referred to the solvent signal. 
Metabolites were purified by Sephadex LH-20 and RP-C18 chromatography.  
Reaction Conditions 
Glucosylated resveratrol derivatives 
Resveratrol (1, RES) and piceid (trans-resveratrol-3-O-β-D-glucopyranoside, 2, PIC) are 
commercially available. Diglucosylated resveratrol derivatives 3 and 4 were prepared as 
reported previously (25). 
Acylated resveratrol derivatives 
3-O-stearoyl-trans-resveratrol (5) was kindly provided by Dr. F. J. Plou. Briefly, preparation 
of 5 involves enzymatic acylation from RES using immobilized lipase from Alcaligenes sp. 
(lipase QLG) as reported previously (48). Piceid acyl derivatives (6-7) were also synthesized 
by enzymatic acylation as described earlier by our group (25). 
Resveratrol sulphate metabolites 
General procedure for the microwave-assisted O-sulfonation and desylilation: 
Microwave based sulfonation reactions were performed using a microwave synthesizer in 
sealed reaction vessels. Sulfur trioxide–trimethylamine complex was previously washed with 
H2O, MeOH, and CH2Cl2 and dried under high vacuum. TBDMS-protected resveratrol 
derivative (1.0 equiv), sulfur trioxide–trimethylamine complex (5 equiv per OH) and a 
magnetic stirrer bar were placed in a 2-5 mL microwave reaction vial and fitted with a 
septum, which was then pierced with a needle. The closed vial was then evacuated under high 
vacuum for 2 h. The mixture was dissolved in dry CH3CN (2.0 mL) and NEt3 (0.3-1.0 mL) 
was then added. Reaction mixture was subjected to microwave radiation for 20–40 min at 
100 ºC (50-60W average power). MeOH (1 mL) and CH2Cl2 (1 mL) were added, and the 
solution was layered on the top of a Sephadex LH-20 chromatography column which was 
eluted with CH2Cl2/MeOH (1:1) to obtain the corresponding triethylammonium salt. The 
product and KF (2.0 equiv) were dissolved in MeOH (5 mL). The reaction mixture was 
stirred at room temperature for 18 h and the solvent was then removed under vacuum. The 
crude was purified by RP-C18 eluting with H2O:CH3OH from 100:0 to 70:30). Fractions 
containing the desired product were concentrated and freeze-dried affording the 
corresponding resveratrol sulphated compounds. Yields were: 8 (73%), 9 (82%) and 10 
(93%). 
 
Biological procedures 
Cell culture 
Cell culture media were purchased from Gibco (Grand Island, NY, USA). Fetal bovine 
serum (FBS) was a product of Harlan-Seralab (Belton, U.K.). Supplements and other 
chemicals not listed in this section were obtained from Sigma Chemicals Co. (St. Louis, Mo., 
USA). Plastics for cell culture were supplied by Thermo ScientificTM BioLite. All tested 
compounds were dissolved in DMSO at a concentration of 10 µg/mL and stored at –20°C 
until use. 
Cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 
glucose (1 g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 µg/mL) and 
amphoterycin (1.25 µg/mL), supplemented with 10% FBS. 
 
Cytotoxicity assays 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical 
Co., St. Louis, MO) dye reduction assay in 96-well microplates was used, as previously 
described (49). Some 5 x 103 cells of HT-29, MCF-7 or HEK-293 cells in a total volume of 
100 µL of their respective growth media were incubated with serial dilutions of the tested 
compounds. After 3 days of incubation (37 °C, 5% CO2 in a humid atmosphere), 10 µl of 
MTT (5 mg/ml in PBS) were added to each well and the plate was incubated for further 4 h 
(37 °C). The resulting formazan was dissolved in 150 µL of 0.04 N HCl/2-propanol and read 
at 550 nm. All determinations were carried out in triplicate. 
ELISA analysis 
HT-29 cells at 70–80% confluence were collected after serum starvation for 24 h. Cells 
were incubated with 20 µg/mL resveratrol in DMSO and with 10 µg/mL of the corresponding 
stilbene in DMSO for 72 h. Culture supernatants were collected and VEGF secreted by HT-
29 cells was determined using Invitrogen Human Vascular Endothelial Growth Factor ELISA 
Kit according to the manufacturer’s instructions.  
 
RT-qPCR analysis 
HT-29 cells at 70–80% confluence were collected after serum starvation for 24 h. Cells were 
incubated with combretastatin derivatives in DMSO (see Figs. 2 and 3) for 48 h. Cells were 
collected and the total cellular RNA from HT-29 cells was isolated using Ambion RNA 
extraction Kit according to the manufacturer’s instructions. The cDNA was synthesized by 
MMLV-RT with 1–21 µg of extracted RNA and oligo(dT)15 according to the manufacturer’s 
instructions.  
Genes were amplified by use of a thermal cycler and StepOnePlus ™ Taqman ® probes. 
TaqMan ® Gene Expression Master Mix Fast containing the appropriate buffer for the 
amplification conditions, dNTPs, thermostable DNA polymerase enzyme and a passive 
reference probe was used. To amplify each of the genes the predesigned primers were used 
and sold by Life Technologies TaqMan ® Gene Expression Assays, Hs99999903-m1 (β-
actin), Hs00900055-m1 (VEGF), Hs00972646-m1 (hTERT) y Hs00153408-m1 (c-MYC). 
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